Search - tctmd.com

Displaying 401 - 420 of 500

Sort: Relevancy | Date

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

News Daily News

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

February 01, 2019

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

Flu Tied to Worse Outcomes in Patients Hospitalized With Heart Failure

News Daily News

Flu Tied to Worse Outcomes in Patients Hospitalized With Heart Failure

January 03, 2019

TCTMD’s Top 10 Most Popular Stories for December 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

January 01, 2019

Top News in Heart Failure: 2018

News Features

Top News in Heart Failure: 2018

December 28, 2018

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

December 18, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

November 13, 2018

Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

November 11, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

News Daily News

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

October 30, 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

Aspirin Falters Yet Again in Primary Prevention: ASPREE

News Daily News

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Michael O'Riordan

September 17, 2018

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

News Daily News

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

September 13, 2018

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.